FPGEE 2026 Practice Exam for NABP – The Complete All-in-One Guide to Exam Success!

The correct answer is that prescribers can prescribe Thalomid (thalidomide) therapy without automatic refills for a period of 4 weeks. This limitation is primarily due to the strict regulations surrounding the use of Thalomid, which is a medication that can cause severe birth defects and other serious side effects. Given this risk, the prescribing of Thalomid is closely monitored, and the 4-week limit helps ensure that patients are regularly evaluated by their healthcare providers.

In terms of regulatory guidelines, this requirement serves to minimize risks associated with the medication while ensuring that patients have timely access to their prescriptions, promoting continuous patient-provider engagement. In contrast, some of the other durations suggested (such as 2 weeks, 6 weeks, or 1 month) do not align with the established guidelines, which set a clear framework for safe prescribing practices regarding Thalomid therapy. This is crucial for patient safety and adherence to monitoring protocols.